About NeuroMetrix (NASDAQ:NURO)
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:NURO
- CUSIP: N/A
- Web: www.neurometrix.com
- Market Cap: $3.63 million
- Outstanding Shares: 2,126,000
- 50 Day Moving Avg: $1.99
- 200 Day Moving Avg: $2.08
- 52 Week Range: $0.38 - $4.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: -0.01
- Annual Revenue: $15.72 million
- Price / Sales: 0.23
- Book Value: $2.83 per share
- Price / Book: 0.60
- EBITDA: ($13,270,000.00)
- Net Margins: -83.92%
- Return on Equity: -209.56%
- Return on Assets: -135.03%
- Current Ratio: 2.13%
- Quick Ratio: 1.73%
- Average Volume: 62,842 shs.
- Beta: 0.41
- Short Ratio: 1.7
Frequently Asked Questions for NeuroMetrix (NASDAQ:NURO)
What is NeuroMetrix's stock symbol?
NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."
When did NeuroMetrix's stock split? How did NeuroMetrix's stock split work?
NeuroMetrix shares reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of NeuroMetrix stock prior to the reverse split would have 13 shares after the split.
How were NeuroMetrix's earnings last quarter?
NeuroMetrix, Inc. (NASDAQ:NURO) released its earnings results on Thursday, July, 21st. The company reported ($42.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($7.44) by $35.52. The company earned $2.65 million during the quarter, compared to analyst estimates of $1.22 million. NeuroMetrix had a negative net margin of 83.92% and a negative return on equity of 209.56%. View NeuroMetrix's Earnings History.
Where is NeuroMetrix's stock going? Where will NeuroMetrix's stock price be in 2017?
1 brokers have issued twelve-month price objectives for NeuroMetrix's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate NeuroMetrix's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for NeuroMetrix.
Who are some of NeuroMetrix's key competitors?
Some companies that are related to NeuroMetrix include Bio Blast Pharma (ORPN), Senesco Technologies (SVON), OncoGenex Pharmaceuticals (ACHV), Strata Skin Sciences (SSKN), Rosetta Genomics (ROSG), Windtree Therapeutics (WINT), Affymax (AFFY), Tetralogic Pharmaceuticals Corp (TLOG), Adeptus Health (ADPT), Caladrius Biosciences (CLBS), DNIB Unwind (BIND), Echo Therapeutics (ECTE), Epirus Biopharmaceuticals (EPRS), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX), Parnell Pharmaceuticals Holdings Ltd (PARN), Secure Point Technologies (IMSC) and Sunshine Heart (SSH).
Who are NeuroMetrix's key executives?
NeuroMetrix's management team includes the folowing people:
- Shai N. Gozani M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer, Secretary
- Thomas T. Higgins, Chief Financial Officer, Senior Vice President, Treasurer
- Francis X. McGillin, Senior Vice President, General Manager - Consumer Wearables
- David E. Goodman M.D., Independent Director
- Allen J. Hinkle M.D., Independent Director
- Nancy E. Katz, Independent Director
- Timothy R. Surgenor, Independent Director
- David Van Avermaete, Independent Director
How do I buy NeuroMetrix stock?
Shares of NeuroMetrix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeuroMetrix's stock price today?
MarketBeat Community Rating for NeuroMetrix (NASDAQ NURO)MarketBeat's community ratings are surveys of what our community members think about NeuroMetrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of NeuroMetrix stock can currently be purchased for approximately $1.71.
Earnings History for NeuroMetrix (NASDAQ:NURO)Earnings History by Quarter for NeuroMetrix (NASDAQ NURO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/20/2017||Q2 2017||($2.83)||($2.49)||$4.40 million||$4.31 million||View||N/A|
|4/20/2017||Q1 2017||($3.92)||($7.28)||$4.17 million||$4.31 million||View||N/A|
|1/26/2017||Q416||($6.00)||($4.16)||$3.48 million||$3.70 million||View||Listen|
|10/20/2016||Q316||($6.56)||($6.08)||$3.01 million||$3.39 million||View||Listen|
|7/21/2016||Q216||($7.44)||($42.96)||$1.22 million||$2.65 million||View||Listen|
|4/21/2016||Q116||($7.60)||($8.00)||$2.65 million||$2.28 million||View||Listen|
|10/22/2015||Q315||($0.64)||($2.08)||$6.47 million||$2.10 million||View||Listen|
|7/22/2015||Q215||($3.84)||$9.80 million||$1.22 million||View||Listen|
|2/12/2015||Q414||($2.88)||$4.62 million||$1.41 million||View||N/A|
|7/24/2014||Q413||($6.80)||$1.16 million||$1.34 million||View||N/A|
|10/23/2013||Q313||($2.08)||$1.77 million||$1.31 million||View||Listen|
|7/25/2013||Q2 2013||($7.36)||$2.20 million||$1.20 million||View||N/A|
Earnings Estimates for NeuroMetrix (NASDAQ:NURO)
Next Year EPS Consensus Estimate: $-4.5 EPS
Dividend History for NeuroMetrix (NASDAQ:NURO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NeuroMetrix (NASDAQ:NURO)
Insider Ownership Percentage: 4.40%Insider Trades by Quarter for NeuroMetrix (NASDAQ:NURO)
Institutional Ownership Percentage: 6.53%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/21/2017||Thomas T Higgins||Insider||Buy||1,000||$2.83||$2,830.00|| |
|6/16/2017||Shai Gozani||CEO||Buy||3,500||$2.90||$10,150.00|| |
|6/15/2017||Thomas T Higgins||Insider||Buy||3,500||$2.98||$10,430.00|| |
|6/14/2017||Shai Gozani||CEO||Buy||5,000||$2.97||$14,850.00|| |
|6/14/2017||Thomas T Higgins||Insider||Buy||2,300||$2.97||$6,831.00|| |
|11/1/2016||Shai Gozani||CEO||Buy||3,000||$1.31||$3,930.00|| |
|10/28/2016||Thomas T Higgins||Insider||Buy||3,000||$1.32||$3,960.00|| |
|10/27/2016||Shai Gozani||CEO||Buy||6,000||$1.32||$7,920.00|| |
|8/31/2016||Thomas T Higgins||CFO||Buy||1,400||$1.41||$1,974.00|| |
|8/18/2016||Shai Gozani||CEO||Buy||5,000||$1.49||$7,450.00|| |
|8/12/2016||Thomas T Higgins||Insider||Buy||2,000||$1.45||$2,900.00|| |
|6/1/2016||Shai Gozani||CEO||Buy||2,500||$1.71||$4,275.00|| |
|5/23/2016||Francis X Mcgillin||VP||Buy||1,000||$1.65||$1,650.00|| |
|5/19/2016||Shai Gozani||CEO||Buy||12,000||$1.55||$18,600.00|| |
|5/19/2016||Thomas T Higgins||CFO||Buy||3,200||$1.54||$4,928.00|| |
|8/28/2015||Thomas T Higgins||CFO||Buy||4,500||$0.92||$4,140.00|| |
|8/20/2015||Thomas T Higgins||CFO||Buy||5,500||$0.91||$5,005.00|| |
|8/11/2015||Shai Gozani||CEO||Buy||16,300||$0.91||$14,833.00|| |
|11/9/2012||Shai Gozani||CEO||Buy||26,800||$0.55||$14,740.00|| |
|8/27/2012||Krishnamurthy Balachandran||COO||Buy||5,000||$0.67||$3,350.00|| |
|8/21/2012||Thomas T Higgins||CFO||Buy||5,000||$0.64||$3,200.00|| |
|8/13/2012||Krishnamurthy Balachandran||COO||Buy||5,000||$0.70||$3,500.00|| |
|8/8/2012||Thomas T Higgins||CFO||Buy||5,000||$0.70||$3,500.00|| |
Headline Trends for NeuroMetrix (NASDAQ:NURO)
Latest Headlines for NeuroMetrix (NASDAQ:NURO)
Loading headlines, please wait.
NeuroMetrix (NURO) Chart for Sunday, October, 22, 2017